NCT07770646Not yet recruitingPhase 4
A Pragmatic Trial of Interleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necrosis Factor-alpha Inhibitor Failure in Axial Spondyloarthritis
A Pragmatic Randomized Pilot Trial of Interleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necrosis Factor-alpha Inhibitor Failure in Axial Spondyloarthritis
Source: ClinicalTrials.gov · Last updated 14 Oct 2026
Brief summary (registry, in English)
The purpose of this study is to determine the feasibility of conducting a pragmatic trial of IL-17i versus JAKi in adults with axial spondyloarthritis (axSpA) who have failed at least one tumor necrosis factor-alpha inhibitor (TNFi), to estimate the effectiveness of IL-17i versus JAKi at 16 weeks and to determine additional effectiveness measures, safety, and treatment persistence of IL-17i versus JAKi
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 12 Aug 2026
- Start date
- 1 Nov 2026
- Primary completion date
- 15 Sept 2028
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Diseases
- Ankylosing spondylitis
- NCT number
- NCT07770646
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 40
- From 1 Nov 2026 to the primary completion date, 15 Sept 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previously received an IL-17i or JAKi
- Concomitant use of other biologic or targeted synthetic disease-modifying anti-rheumatic drug (tsDMARD) therapy
Other illness
- Active infection requiring antimicrobials
Lab values
- Contraindications to either treatment arm:
- Inflammatory bowel disease (IBD)- Crohn's disease or Ulcerative Colitis
- Active cancer or cancer remission within the past 3 years (apart from non-melanoma skin cancer (NMSC) and cervical intraepithelial neoplasia (CIN)
- History of stroke, heart attack, or blood clots (venous or arterial)
- Cirrhosis
- End-stage renal disease (GFR \<15) or dialysis
- Human Immunodeficiency Virus (HIV) positive
- Pregnant or lactating
Who the study is looking for
- fulfill ASAS classification criteria for axSpA and/or modified New York classification criteria for AS
- Active axSpA (ASDAS ≥ 2.1 and/or BASDAI ≥ 4)
- Failure of or intolerance to ≥1 TNF
- Participants of reproductive potential must agree to use any form of effective contraception during the study period, in accordance with standard clinical practice and FDA labeling for the assigned study medication
- Ability to provide informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The University of Texas Health Science Center at Houston Coordinator of this site? Confirm its status | Houston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.